Comparative Pharmacology
Head-to-head clinical analysis: MYCOPHENOLATE MOFETIL HYDROCHLORIDE versus MYCOPHENOLATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCOPHENOLATE MOFETIL HYDROCHLORIDE versus MYCOPHENOLATE SODIUM.
MYCOPHENOLATE MOFETIL HYDROCHLORIDE vs MYCOPHENOLATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mycophenolate mofetil hydrochloride is a prodrug of mycophenolic acid (MPA), a selective, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This enzyme is crucial for de novo guanosine nucleotide synthesis in T and B lymphocytes, leading to inhibition of lymphocyte proliferation and antibody production.
Mycophenolate sodium is a prodrug that is hydrolyzed to mycophenolic acid (MPA), a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH is a key enzyme in the de novo synthesis of guanine nucleotides, which is crucial for T- and B-lymphocyte proliferation. MPA preferentially inhibits the type II isoform of IMPDH expressed in activated lymphocytes, thereby exerting immunosuppressive effects.
Oral: 1-1.5 g twice daily; intravenous: 1 g over 2 hours twice daily.
720 mg orally twice daily, administered as two 360 mg tablets or two 180 mg capsules. Intravenous infusion: 720 mg intravenously over 2 hours twice daily, for patients unable to tolerate oral therapy.
None Documented
None Documented
The terminal elimination half-life of MPA is approximately 17.9 hours (range 11.7–30.9 hours) in healthy volunteers. In renal transplant patients, half-life may be prolonged to 16.6 ± 6.2 hours. This supports twice-daily dosing with monitoring of trough levels for efficacy and toxicity.
The terminal elimination half-life of mycophenolic acid is approximately 8-16 hours in healthy subjects and renal transplant patients. The half-life of the inactive glucuronide metabolite (MPAG) is longer (16-18 hours) and accumulates in renal impairment.
Mycophenolic acid (MPA), the active metabolite, is primarily excreted in urine as the glucuronide conjugate (MPAG). Approximately 87% of an administered dose is recovered in urine, with <1% as unchanged MPA. Fecal excretion accounts for about 6% of the dose, mainly as MPAG via biliary secretion.
Mycophenolate sodium is excreted primarily in urine as mycophenolic acid (MPA) and its glucuronide metabolite (MPAG). Renal excretion accounts for approximately 87% of the dose, with <1% excreted as unchanged MPA. Fecal excretion represents about 6%.
Category D/X
Category C
Immunosuppressant
Immunosuppressant